Health care costs in patients with fibromyalgia on pregabalin vs. duloxetine

Pain Practice

Volumn 12, Issue 1, 2012, Pages 14-22

  Burke, James P ^a   Sanchez, Robert J ^b   Joshi, Ashish V ^b   Cappelleri, Joseph C ^b   Kulakodlu, Mahesh ^a   Halpern, Rachel ^a  

^a i3 Innovus   (United States)

^b PFIZER INC   (United States)

Author keywords

Costs; Duloxetine; Fibromyalgia; Health care utilization; Pregabalin

Indexed keywords

DULOXETINE; PREGABALIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG COST; ECONOMIC ASPECT; FEMALE; FIBROMYALGIA; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MULTIVARIATE ANALYSIS; PRESCRIPTION; RETROSPECTIVE STUDY;

EID: 84855727551     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2011.00470.x     Document Type: Article

References (26)

1. Bennett RM. Clinical manifestations and diagnosis of fibromyalgia. Rheum Dis Clin North Am. 2009;35:215-232.
2. Bennett RM, Schein J, Kosinski MR, et al. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum. 2005;53:519-527.
3. Staud R, Vierck CJ, Cannon RL, et al. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain. 2001;91:165-175.
4. Chakrabarty S, Zoorob R. Fibromyalgia. Am Fam Physician. 2007;76:247-254.
5. Chong YY, Ng BY. Clinical aspects and management of fibromyalgia syndrome. Ann Acad Med Singapore. 2009;38:967-973.
6. Verbunt JA, Pernot DH, Smeets RJ. Disability and quality of life in patients with fibromyalgia. Health Qual Life Outcomes. 2008;6:8.
7. Bradley LA. Pathophysiologic mechanisms of fibromyalgia and its related disorders. J Clin Psychiatry. 2008;69(suppl 2):6-13.
8. Verdejo-García A, López-Torrecillas F, Calandre EP, et al. Executive function and decision-making in women with fibromyalgia. Arch Clin Neuropsychol. 2009;24:113-122.
9. National Fibromyalgia Association Website. Fibromyalgia economic burden. Available at: Accessed May 2011.
10. Navarro RP. Contemporary management strategies for fibromyalgia. Am J Manag Care. 2009;15:S197-S218.
11. Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010;11:505-521.
12. Häuser W, Arnold B, Eich W, et al. Management of fibromyalgia syndrome - an interdisciplinary evidence-based guideline. Ger Med Sci. 2008;6:Doc14.
13. Arnold LM, Clauw DJ. Fibromyalgia syndrome: practical strategies for improving diagnosis and patient outcomes. Am J Med. 2010;123:S2.
14. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139.
15. Gore M, Sadosky A, Tai K, Stacey B. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Clin Ther. 2007;29:1655-1670.
16. Rosner B. Fundamentals of Biostatistics. 7th ed. Boston: Brooks/Cole; 2010.
17. Wooldridge JM. Introductory Econometrics: A Modern Approach. Cincinnati, OH: Southwestern College Publishing, A Division of Thomson Learning; 2000.
18. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1998:225-229.
19. Berger A, Dukes E, Martin S, et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract. 2007;61:1498-1508.
20. Palacio A, Uribe CL, Li H, et al. Financial and clinical characteristics of fibromyalgia: a case-control comparison. Am J Manag Care. 2010;16:S118-S125.
21. Berger A, Sadosky A, Dukes EM, et al. Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia. Am J Manag Care. 2010;16:S126-S137.
22. White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med. 2008;50:13-24.
23. Choy E, Richards S, Bowrin K, et al. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. Curr Med Res Opin. 2010;26:965-975.
24. Zhao Y, Sun P, Watson P, et al. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract. 2011;11:204-216.
25. Silverman S, Dukes EM, Johnston SS, et al. The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. Curr Med Res Opin. 2009;25:829-840.
26. Harnett J, Margolis J, Cao Z, et al. Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine. Pain Pract. 2011;11:217-229.